ArticleFrontiers in pharmacology2025
Revealing the mechanisms of warfarin-induced vascular calcification through metabolomics and network toxicology.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isowighteone attenuates vascular calcification by targeting HSP90AA1-mediated PI3K-Akt pathway and suppressing osteogenic gene expression.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warfarin is widely used in clinical anticoagulation therapy, but the exact mechanism by which it induces vascular calcification (VC) remains unclear. This study aimed to explore the mechanisms of warfarin-induced VC using metabolomics and network toxicology approaches. Initially, normal rats were orally administered warfarin for 2 weeks, and VC was then assessed by serum biochemistry and histopathology. Subsequently, non-targeted metabolomics was performed to analyze serum metabolite changes. Finally, network toxicology analysis was conducted to identify key targets and signaling pathways associated with warfarin-induced VC, which were further validated using molecular docking, qRT-PCR, and western blot analyses. The results indicated that warfarin induced aortic calcification in rats, and metabolomics identified 32 differential metabolites, mainly involved in pathways such as primary bile acid biosynthesis, steroid hormone biosynthesis, and amino acid metabolism. Network toxicology analysis, molecular docking, and experimental validation showed that warfarin may induce VC by modulating the targets AKT1, TP53, and HSP90AA1, thereby influencing the PI3K-AKT signaling pathway. This study reveals the potential molecular mechanisms underlying warfarin-induced VC, laying a foundation for further mechanistic investigations and providing important insights for the rational clinical application of warfarin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.